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Serotonin (5-hydroxytryptamine; 5-HT) is most commonly known for its role as a
neurotransmitter in the central nervous system (CNS). However, the majority of the body’s
5-HT is produced in the gut by enterochromaffin (EC) cells. Alterations in 5-HT signaling
have been associated with various gut disorders including inflammatory bowel disease
(IBD), irritable bowel syndrome (IBS) and enteric infections. Recently, our studies have
identified a key role for 5-HT in the pathogenesis of experimental colitis. 5-HT7 receptors
are expressed in the gut and very recently, we have shown evidence of 5-HT7 receptor
expression on intestinal immune cells and demonstrated a key role for 5-HT7 receptors
in generation of experimental colitis. This review summarizes the key findings of these
studies and provides a comprehensive overview of our current knowledge of the 5-HT7
receptor in terms of its pathophysiological relevance and therapeutic potential in intestinal
inflammatory conditions, such as IBD.
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INTRODUCTION
The gastrointestinal (GI) tract contains an extensive system of
endocrine cells that are interspersed amongst gut epithelial cells
(Rehfeld, 1998). There are several subpopulations of endocrine
cells, which release various biologically active compounds such
as gastrin, secretin, cholecystokinin, chromogranin, and sero-
tonin (5-hydroxytryptamine; 5-HT; Sharkey and Mawe, 2002).
Enterochromaffin (EC) cells are the best characterized subset of
enteric endocrine cells and constitute the largest endocrine cell
population in the gut (Ham, 2002; Sharkey and Mawe, 2002; Ku
et al., 2006; Gunawardene et al., 2011). EC cells arise from multi-
potent stem cells located near the base of the crypts of Lieberkühn
and are the body’s main source of 5-HT (Sharkey and Mawe,
2002; Gunawardene et al., 2011). Alterations in EC cells and 5-
HT signaling has been shown to be associated in a number of GI
disorders including inflammatory bowel disease (IBD), irritable
bowel syndrome (IBS), and enteric infections, emphasizing the
importance of 5-HT signaling in intestinal homeostasis.
5-HT mediates many GI functions, including secretion and
peristalsis, by activating of a diverse range of 5-HT receptors
(Mawe and Hoffman, 2013). To date, seven types of 5-HT recep-
tors have been identified and amongst these, five are expressed
within the GI tract. This paper reviews information on the most
recently identified class of 5-HT receptors, 5-HT7, and its role in
the GI tract with a focus on its implications in understanding the
pathophysiology of intestinal disorders.
5-HT IN THE GI TRACT
5-HT is a highly conserved biogenic amine that is found in
separate peripheral and central tissue pools that are distinctly
regulated by two different rate-limiting enzymes, tryptophan
hydroxylase (TpH) 1 and 2, respectively (Walther and Bader,
2003; Walther et al., 2003). TpH1 found in EC cells catalyzes the
majority of 5-HT production in the body (roughly∼90%). TpH1
converts dietary L-tryptophan to 5-hydroxytryptophan (5-HTP),
which is then converted to 5-HT by L-amino acid decarboxy-
lase (Bertrand and Bertrand, 2010). Once synthesized, 5-HT is
packaged into granules by the vesicular monoamine transporter
1 (VMAT1; Rindi et al., 2004; Schäfermeyer et al., 2004) and
released mainly from granules stored near the basal border of
the EC cell, though some studies have identified granules near
the apical membrane (Nilsson et al., 1987). EC cells release 5-
HT in response to various mechanical and chemical stimuli,
including bacterial toxins, in a calcium-dependent manner (Racké
et al., 1996; Mössner and Lesch, 1998). Once released, 5-HT
participates in various gut functions, including secretion and
peristalsis, by activation of a diverse range of 5-HT receptors
located in the lamina propria (LP; Mawe and Hoffman, 2013).
The actions of 5-HT are terminated by uptake by the sero-
tonin reuptake transporter (SERT) into adjacent epithelial cells
(Martel et al., 2003) and degradation by monoamine oxidase A
(MAOA). SERT is also found in platelets and enteric neurons
(Bertrand and Bertrand, 2010), and is the target for important
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therapeutic drugs such as fluoxetine and citalopram, members
of the family of serotonin-selective reuptake inhibitors (SSRIs).
SERT mediated reuptake of 5-HT can be partially replaced
by the dopamine transporter (DAT) and organic cation trans-
porter (OCT), albeit at a lower affinity than SERT (Chen et al.,
2001).
5-HT SIGNALING IN INTESTINAL INFLAMMATION
IBDs, Crohn’s disease (CD) and ulcerative colitis (UC), are
serious chronic inflammatory conditions of the human bowel
currently affecting approximately 1–2 million people in the US
and Canada (Loftus, 2004). Although the pathogenesis of IBD
remains unknown, it is a multifactorial disease that involves
both genetic and environmental components. As such, IBD is
considered to be an inappropriate immune response that occurs
in genetically susceptible individuals as a result of a complex
interaction between environmental factors, microbial factors, and
the intestinal immune system (Bouma and Strober, 2003; Bern-
stein and Shanahan, 2008; Koloski et al., 2008; Arnett and Viney,
2010). During the past five decades, the frequency of IBD has
increased rapidly in highly industrialized Western nations with
Canada having one of the highest incidence rates of both UC and
CD worldwide (Fedorak et al., 2010).
Alterations in 5-HT signaling have been observed in IBD
(Ahonen et al., 1976; Belai et al., 1997; El-Salhy et al., 1997;
Magro et al., 2002; Coates et al., 2004) and changes to EC cell
numbers and 5-HT content have been associated with both UC
and CD (Bishop et al., 1987; Belai et al., 1997; El-Salhy et al.,
1997). Changes in 5-HT signaling have also been shown in various
experimental models of intestinal inflammation, including tri-
nitrobenzene sulphonic acid (TNBS), di-nitrobenzene sulphonic
acid (DNBS), and dextran sulfate sodium (DSS; Oshima et al.,
1999; Linden et al., 2005; Khan et al., 2006). In all of these models,
EC cell numbers and 5-HT levels are increased. In addition, infec-
tion with either Trichuris muris or Citrobacter rodentium, leads
to an increase in EC cells numbers and/or 5-HT release, further
supporting a role for 5-HT in inflammatory states (O’Hara et al.,
2006; Motomura et al., 2008).
5-HT itself also plays a key role in the generation of intesti-
nal inflammation. Previously, we have shown that there is sig-
nificant reduction in intestinal inflammation post- DSS and
DNBS-induced colitis when intestinal 5-HT levels are reduced by
genetic deletion of the rate-limiting TpH1 enzyme or by using
parachlorophenylalanine (pCPA), while replenishing 5-HT levels
intensifies colitis severity (Ghia et al., 2009). In turn, studies
have also shown that chemical-induced colitis or spontaneous
colitis associated with an IL-10 deficiency is increased in severity
when coupled with the 5-HT enhancing effects of a knockout of
SERT (Bischoff et al., 2009; Haub et al., 2010). Prior approaches
aimed at blocking 5-HT synthesis by a pharmacological agent
through inhibition of TpH, as with pCPA, have been impeded
by adverse effects to brain 5-HT synthesis leading to alterations
in central nervous system (CNS)-mediated functions (Ruhé et al.,
2007). Recently, we have also shown that blocking 5-HT synthesis
using an orally-delivered small molecule TpH inhibitor, telotristat
etiprate (LX1032/LX1606), effectively reduces peripheral 5-HT
synthesis and both chemical- and infection-induced intestinal
inflammation (Kim et al., 2013b). This compound is unable to
cross the blood-brain barrier (Savelieva et al., 2008) and does not
appear to affect enteric neuronal TpH2 (Margolis et al., 2013).
Oral administration of LX1606 significantly depletes intestinal
5-HT levels but does not affect brain 5-HT levels. Margolis
et al. (2013) also evaluated the effect of LX1606 on neuronal
5-HT stores using immunocytochemical techniques and found
that LX1606 did not affect the proportion of myenteric 5-HT-
immunoreactive neurons or the area of myenteric plexus occupied
by 5-HT-immunoreactive nerve fibers. This suggests that while
LX1606 significantly depletes 5-HT stores from EC cells, entire
neuronal 5-HT stores are maintained and therefore, LX1606 and
similarly related peripheral TpH inhibitors appear to fail to enter
the myenteric plexus and/or inhibit enteric neuronal TpH2.
The precise mechanisms by which 5-HT exerts its pro-
inflammatory actions remains to be determined. To elucidate
this mechanism, we assessed the role of 5-HT in dendritic cell
(DC) function in relation to gut inflammation. EC cells are
located in very close proximity to or in contact with immune
cells such as DCs (Yang and Lackner, 2004) and studies from
our lab and others have shown an important role for 5-HT in
immune regulation and in turn, immune-mediated alteration
of EC cells/5-HT signaling (Wang et al., 2007; Li et al., 2011;
Shajib et al., 2013). DCs are professional antigen-presenting cells
with the ability to initiate adaptive immune responses. Intestinal
DCs reside in the LP as such, are able to continuously sam-
ple luminal contents. DCs play a critical role in orchestrating
immune responses and have been shown to be important in the
generation of intestinal inflammation (Lipscomb and Masten,
2002; Berndt et al., 2007). DCs isolated from TpH1 deficient
mice following DSS administration release significantly less IL-
12 compared with DCs isolated from wild-type mice (Li et al.,
2011). Interestingly, when DCs isolated from TpH1 deficient mice
are cultured in the presence of 5-HT, this restores IL-12 levels
to those comparable to DCs from wild-type mice suggesting a
role of 5-HT mediated activation of DCs. Furthermore, when
5-HT stimulated DCs are transferred back into TpH1 deficient
mice, there is significant increase in colitis severity and this is
associated with higher myeloperoxidase (MPO) activity and pro-
inflammatory cytokine (IL-1β and IL-6) levels. This suggests that
5-HT mediated modulation of DC function is important in the
pathogenesis of colitis though research targeting 5-HT signaling is
needed to translate these observations for clinical utilization and
to design a therapeutic strategy for colitis.
INTESTINAL INFLAMMATION AND THE GUT-BRAIN-AXIS
The gut-brain-axis is a bi-directional neuro-humoral communi-
cation system that links gut and brain function in health and
disease, and contributes to GI functions, including motility, secre-
tion, visceral sensations, and mucosal immunity (Collins and
Bercik, 2009; El Aidy et al., 2012; Forsythe and Kunze, 2013). The
importance of this axis is demonstrated by its role in IBS and is
reflected in the high prevalence of psychiatric morbidity in IBS
(Whitehead et al., 2002). There is also growing evidence that the
gut-brain-axis plays a role in IBD (Graff et al., 2009; Bonaz and
Bernstein, 2013). IBD results in high morbidity and mortality
and severely compromises quality of life and life expectancy. In
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recent years, there has been increasing recognition that depression
can worsen the course of IBD (Mardini et al., 2004; Mittermaier
et al., 2004; Persoons et al., 2005) and it has been shown that
persons with IBD have higher rates of depression (in addition
to panic, generalized anxiety, obsessive-compulsive disorders)
compared with control populations (Walker et al., 2008). The
mechanisms underlying this relationship in terms of cause-and-
effect are currently unclear. In a study by Walker et al. (2008),
it was reported that patients with IBD have a higher 12-month
and also lifetime prevalence of major depression whereby approx-
imately half experienced a first episode of depression more than
2 years before the onset of IBD. Depression may also negatively
affect the course and outcome of disease. A prospective study by
Mittermaier et al. (2004) found that in patients with IBD, those
with significant depressive symptoms (at baseline) had relapses
that occurred sooner and more frequently. In patients with CD,
major depressive disorder has been reported as a risk factor for
failure to achieve remission with infliximab treatment and an
earlier need for retreatment (Persoons et al., 2005). In addition,
studies have found that patients with active disease report higher
levels of depression and anxiety while those with quiescent disease
report lower levels (Porcelli et al., 1996; Levenstein, 2002; Larsson
et al., 2008). As such, it has been proposed that treatments that
improve mood may be useful in improving symptoms and disease
activity in IBD. Antidepressants such as SSRIs are generally well
tolerated and are successful in relieving psychological symptoms
in about 30–40% of patients (Trivedi et al., 2006; Krishnan and
Nestler, 2008). Recently, it was reported that antidepressants
used to treat concomitant mood disorders in patients with IBD
improves relapse rates and use of corticosteroids when compared
with matched controls. Whether this occurred through a direct
effect of the drug on the GI tract, or indirectly via improvement
in mood and stress response was not investigated (Goodhand
et al., 2012). Uncontrolled case report studies have also reported
improvements not only in depression but also in IBD symptom
scores (Mikocka-Walus et al., 2006). In contrast, data from a
single open-label study of SSRI in IBD patients with depression
reported improvements in depression but not in IBD activity
(Walker et al., 1996). Moving forward, there is a need for ran-
domized controlled trials to assess the effects of antidepressants
such as SSRIs on disease activity in patients with IBD.
Studies using animal models have provided insight into mech-
anisms involved in the gut-brain-axis during GI inflammation
and infection. Lyte et al. (1998) showed that mice treated orally
with Campylobacter jejuni had increased anxiety-like behavior
compared to saline-treated control mice. This was without any
increase in inflammatory mediators and likely due to activation
of vagal ascending pathways. In experimental models that result
in increased GI inflammation, there are increases in anxiety-like
behavior. In animal models of colitis, mice treated with DSS
show increased anxiety-like behavior (Bercik et al., 2011). In
addition, mice infected with Trichuris muris demonstrated intesti-
nal inflammation that was associated with increased anxiety-like
behavior when tested using the light/dark test and step-down test
methods (Bercik et al., 2010). This was accompanied by decreased
brain derived neurotropic factor (BDNF) expression in the hip-
pocampus, and elevated levels of TNF-α, INF-γ, and kynurenine.
Abnormal behavior (but not BDNF levels) was normalized by
treatment with immunomodulators, etanercept and budesonide.
Interestingly, both behavior and BDNF levels normalized follow-
ing administration with probiotic Bifidobacterium longum sug-
gesting a role for gut microbiota in modulating behavior. The role
of the microbiota on the gut-brain-axis, however, is beyond the
scope of this review, and has been extensively reviewed elsewhere
(Cryan and O’Mahony, 2011; Collins et al., 2012). What is clear
from the growing body of literature, is that the gut microbiome
plays a critical role in regulating normal function of the gut-
brain axis. Recently, there is a growing body of evidence looking
at the role of 5-HT and the gut microbiome suggesting that 5-
HT may be critically involved at every level of the brain-gut-
microbiome axis (as reviewed by O’Mahony et al., 2014). With
a better understanding of the interaction between this axis and
the 5-HT system, this could aid in the design and development
of novel therapeutic strategies for intestinal disorders that target
5-HT signaling with far-reaching effects beyond the gut. This may
be particularly relevant in GI inflammatory disorders such as IBS
and IBD with reported psychiatric comorbidities.
5-HT7 RECEPTORS IN THE GUT
The discovery of 5-HT in the late 1940s was shortly followed
by evidence for 5-HT receptor heterogeneity. To date, seven
distinct families of 5-HT receptors have been identified, with
some families consisting of various subpopulations (Hoyer et al.,
2002). Five of the seven known families (5-HT1, 5-HT2, 5-HT3,
5-HT4, and 5-HT7 receptors) are expressed in the gut (Hoyer
et al., 2002), with the 5-HT3 and 5-HT4 receptor subtypes being
the most extensively studied. 5-HT3 and 5-HT4 receptors have
been targeted for the treatment of diarrhea and constipation,
respectively (Mawe and Hoffman, 2013). The 5-HT7 receptor is
the most recently discovered member of the 5-HT receptor family
and has since been cloned in rat (Lovenberg et al., 1993; Meyerhof
et al., 1993; Ruat et al., 1993; Shen et al., 1993), mouse (Plassat
et al., 1993), guinea pig (Tsou et al., 1994), porcine (Bhalla et al.,
2002), and human (Bard et al., 1993).
The 5-HT7 receptor is expressed in both the CNS and in
peripheral tissues. In the CNS, pharmacological and animal stud-
ies using 5-HT7 receptor deficient mice have established roles for
the 5-HT7 receptor in control of circadian rhythms and ther-
moregulation (Lovenberg et al., 1993; Tsou et al., 1994; Hedlund
et al., 2003), learning and memory (Roberts and Hedlund, 2012),
and mood disorders including depression (Hedlund, 2009; Mnie-
Filali et al., 2009). In the periphery, 5-HT7 receptors have been
found to be expressed in the colon, ileum, and stomach with low
expression in the spleen, liver, and kidney (Bard et al., 1993).
5-HT7 receptors have also been reported to be expressed on
human enterocyte-like cell line, Caco-2 cells, and was found to
modulate SERT activity (Iceta et al., 2009). Blood-derived DCs
also express the 5-HT7 receptor (Shen et al., 1993; Vanhoenacker
et al., 2000; Idzko et al., 2004).
Specifically within the gut, 5-HT7 receptors are expressed on
smooth muscle cells, enteric neurons, and within the solitary
intestinal lymphoid tissue, small-sized intestinal lymphoid struc-
tures scattered through the small intestine (Tonini et al., 2005;
Guseva et al., 2014). Recently, we have shown that the 5-HT7
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receptor is also expressed on intestinal LP DCs (Kim et al.,
2013a; Figure 1). DCs represent a heterogeneous population with
functional diversity with different DC subsets having distinct sets
of cell surface antigens. Although CD11c is the classical integrin
marker used to distinguish DCs from macrophages (whereby
CD11b+ CD11c− and CD11b+/− CD11chigh are classified as
macrophages and DCs, respectively), this becomes more difficult
when distinguishing between LP macrophage and DC popu-
lations, as LP macrophages express both CD11b and CD11c
markers (Mowat and Bain, 2011). Therefore, it is important to
use differential expression of integrin CD103 (αE integrin) to
reliably distinguish between these two populations. We found that
isolated intestinal CD103+ CD11c+ cells were positive for 5-HT7
receptor expression whereas no significant amount was detected
on CD103− CD11c+ cells. Adding to this finding, Guseva et al.
(2014) recently reported that CD11c+ CD86+ cells colocalize with
5-HT7 receptor staining in colon samples collected from both
inflamed and non-inflamed areas of patients with CD. CD86 is
a co-stimulatory molecule found on mature DCs. These findings
suggest that 5-HT7 receptor expressed by DCs may play a role in
modulating intestinal inflammation in this patient population.
Under physiological conditions, there is evidence that 5-HT7
receptors play a role in motility by mediating smooth muscle
relaxation in colon (Prins et al., 1999; Tonini et al., 2005) and
ileum smooth muscle (Carter et al., 1995). In addition, they are
believed to have a role in initiating murine colonic migrating
motor complexes (Dickson et al., 2010). 5-HT7 receptors may also
have a role in inhibition of peristalsis by 5-HT (Tuladhar et al.,
2003; Table 1).
5-HT7 RECEPTOR SIGNALING IN INTESTINAL DISORDERS
IRRITABLE BOWEL SYNDROME
A number of studies have reported altered 5-HT signaling activ-
ity in intestinal disorders. Therapeutic drugs to target selective
modulation of 5-HT activity—including SSRIs, 5-HT3 and 5-HT4
antagonists and agonists, respectively—have been used in the
treatment of functional GI disorders such as IBS (Gershon and
Tack, 2007; Beattie and Smith, 2008). Some of these drugs, how-
ever, have been associated with unwanted side effects (Ladabaum,
2003; Cole et al., 2004) and thus, prompts the need for more
studies on 5-HT and its receptors in GI pathology and patho-
physiology. IBS is a functional bowel disorder in which abdominal
FIGURE 1 | Distribution of 5-HT7 receptors in the gut and
proposed roles in gut function. 5-hydroxytryptamine (5-HT) released
from enterochromaffin cells can act on surrounding 5-HT7 receptors
that are expressed by smooth muscle cells, enteric neurons,
enterocytes, and immune cells. Activation of 5-HT7 receptors can
influence muscle tone, enteric neuron excitation, and have been
proposed to inhibit SERT activity and promote inflammation by
activation of LP dendritic cells (DCs).
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Table 1 | Effects of 5-HT7 receptor activation or inactivation on gut function.
Species/Region 5-HT7 activation/inhibition Effect Reference
Guinea pig ileum Antagonist SB-269970 Restores 5-HT inhibited peristalsis Tuladhar et al. (2003)
Antagonist SB-269970 Inhibits 5-HT inhibited peristalsis (via enteric neurons) Tonini et al. (2005)
Agonist 8-OH-DPAT Elicits relaxation Carter et al. (1995)
Guinea pig mesentary Antagonist SB-269970 Inhibits 5-HT inhibited constriction Chan and von der Weid (2003)
Mouse colon Antagonist SB-269970 Inhibits spontaneous Dickson et al. (2010)
Antagonist SB-258719 colonic migrating motor complexes
Canine stomach Antagonist SB-269970 Inhibits 5-Carboxamidotryptamine (5-CT) Janssen et al. (2002)
induced gastric relaxation
Human colon Antagonist SB-269970 Inhibits 5-HT induced relaxation of Irving et al. (2007)
human colonic circular muscle
Antagonist mesulergine Inhibits 5-HT induced relaxation of circular muscle Prins et al. (1999)
pain and discomfort is associated with altered bowel habits. 5-
HT plays a key role in regulating motor functions of the GI tract
and studies have suggested that 5-HT7 receptors mediate smooth
muscle relaxation, adding to the rationale for investigating 5-HT7
receptor ligands in IBS. In addition, they play a role in regulation
of nociceptive pathways (Meuser et al., 2002) and thus, may
be involved in the pathological mechanisms underlying visceral
paresthesia seen in IBS. Zou et al. (2007) investigated the role of
5-HT7 receptors in the pathogenesis of IBS in a rodent model
and found that 5-HT7 receptor expression was increased in the
hippocampus, hypothalamus, and intestine (ileum and colon)
of IBS groups as compared to controls and this was associated
with higher cAMP levels at these sites. In addition, there is a
high prevalence of comorbid depression and anxiety disorders in
IBS patients (Andresen and Camilleri, 2006). As 5-HT7 receptors
have been linked with depression (although its role in anxiety is
currently inconclusive) (as reviewed by Hedlund, 2009), it may
be an attractive potential therapeutic target for IBS with effects
extending beyond the gut.
INFLAMMATORY BOWEL DISEASE
The role of 5-HT7 receptors in IBD is far less studied. Very
recently, however, Guseva et al. (2014) has reported that 5-HT7
receptor expression is increased in inflamed sections of CD
patients. In addition, using experimental models of colitis, we
have previously reported that 5-HT7 receptor levels are increased
in the colon of mice post- DSS-induced colitis (Kim et al., 2013a).
In addition, Guseva et al. (2014) also found an up-regulation in
5-HT7 receptor expression in cecum and rectum in DSS-treated
animals compared with controls. Ours and other studies have
also shown that the 5-HT7 receptor is expressed on DCs (Idzko
et al., 2004; Kim et al., 2013a; Guseva et al., 2014). EC cells, the
major producer of 5-HT in the gut, are located in close proximity
to these cells and thus, it is likely that there is interplay between
these two systems. We proposed that inhibiting 5-HT signaling
by blocking 5-HT7 receptor function would lead to attenuation
of immune cell activation and subsequent inflammation. Indeed,
we found that blocking 5-HT signaling by using a selective
5-HT7 receptor antagonist (SB-269970) or by genetic deletion of
this receptor alleviated intestinal inflammation in two separate
chemical models of colitis (DSS and DNBS) (Kim et al., 2013a).
This was indicated by lower macroscopic damage of the colon
and less severe histopathological damage as compared to vehicle-
treated controls. In turn, this was associated with a decrease in
various pro-inflammatory markers including MPO and cytokines
IL-1β, IL-6, and TNF-α. The beneficial effects of targeting said
receptor was also seen in a chronic model of DSS-induced colitis.
Furthermore, we identified a role for 5-HT7 receptor mediated
cytokine release by mature DCs isolated from DSS-treated mice.
Similar effects of 5-HT on cytokine secretion have been observed
in monocyte-derived DCs (Müller et al., 2009). Importantly, it
was recently reported that increased 5-HT7 receptor-positive cells
in DSS-treated mice were also positive for CD11c, suggesting that
there is increased amount of 5-HT7 receptor expressing DCs upon
inflammation (Guseva et al., 2014).
By using chimeric mice that were reconstituted with bone
marrow (BM) cells lacking 5-HT7 receptor expression, we found
that wild-type recipients that received BM cells from 5-HT7
receptor deficient donors showed lower disease activity and less
severe histopathological damage (Kim et al., 2013a). This suggests
that 5-HT7 receptor activation on immune cells play a key role in
mediating intestinal inflammation in experimental colitis. Con-
trary to our data, Guseva et al. (2014) found that pharmacological
blockade or genetic deletion of the 5-HT7 receptor in DSS-
induced colitis exacerbated colitis severity in mice. This may in
large be due to the notable differences in experimental design and
housing condition of animals. For instance, Guseva et al. (2014)
administered the 5-HT7 receptor antagonist at a lower dosage
(100 nM) for a shorter period of time, while we administered
the antagonist throughout the duration of the DSS treatment at
a much higher dosing range (20–80 mg/kg).
DCs are important players that orchestrate downstream
immune responses from initial sampling of the luminal envi-
ronment. As such, DCs play a crucial role in priming responses
to Th1 and Th17 cells (important producers of IFN-γ and
IL-17, respectively). We reported alterations in colonic IFN-γ
and IL-17 levels in 5-HT7 receptor antagonist-treated mice post
DSS-induced colitis suggesting that there may be effects on
T-cell responses when 5-HT7 receptor signaling is disrupted
in vivo (Kim et al., 2013a). Further investigation of the role
of 5-HT7 receptor signaling in T-cell function and examina-
tion of the role of DCs and sequential T cell activation in
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the context of gut inflammation will be necessary in order to
elucidate the downstream effects of targeting this receptor in
intestinal inflammation. In addition, the role of 5-HT7 receptor
activation in modulating other DC functions such as immune
cell survival, remain to be determined. Recently, it has been
reported that 5-HT stimulates human macrophage polarization
through 5-HT2B and 5-HT7 receptors pointing to 5-HT as a
potential target for modulating macrophage polarization and the
potential of targeting 5-HT2B and 5-HT7 receptors as therapies
against inflammatory pathologies (de las Casas-Engel et al., 2013).
Future studies investigating the role of these receptors on LP
macrophages in the context of colitis would be interesting to
determine the specific roles the 5-HT7 receptor has on differ-
ent cell types and subpopulations. Given the heterogeneity seen
amongst immune cells in the intestine, it would not be surprising
for 5-HT7 receptor activation to play distinct roles in different cell
types.
ENTERIC INFECTIONS
Alteration in the number of EC cells and 5-HT levels have
been observed in enteric infection (Bearcroft et al., 1996; Spiller
et al., 2000; Turvill et al., 2000; Kordasti et al., 2004; Wheatcroft
et al., 2005). Recently, we examined the role of the 5-HT7
receptor during enteric infection by using a murine model of
large intestinal nematode infection, Trichuris muris. We found
that expulsion of worms was significantly delayed in 5-HT7
receptor deficient mice after T. muris infection and this was
accompanied by an attenuation of infection-induced colonic
muscle contractility. There was reduction in IL-9 levels in 5-HT7
receptor deficient mice as compared to wild-type after infection
(Kim et al., 2012). This suggests that the 5-HT7 receptor plays
an important role in generation of infection-induced intesti-
nal muscle contractility, worm expulsion, and modulation of
immune responses in the context of host defense in enteric
infection.
CONCLUSIONS AND FUTURE DIRECTIONS
There is now abundant evidence in favor of an important
role of 5-HT signaling in various gut disorders including IBD,
IBS, and enteric infections. In the past two decades, there
have been significant advances in our understanding of the
5-HT7 receptor. Despite our best efforts, there are many unan-
swered questions and new avenues of research that still war-
rant investigation. Here, we highlighted the role of this receptor
in the gut specifically in relation to inflammation and func-
tional disorders; however, novel functions and roles for these
receptors continue to emerge. Further elucidating the role of
these receptors in intestinal function, and in intestinal patholo-
gies and pathophysiology will help us to better understand
the underlying mechanisms of various common intestinal dis-
orders such as IBD and IBS, and will ultimately lead to the
development of novel therapies. Further studies investigating
5-HT7 receptor signaling in human samples from IBD patients
and targeted inhibition of 5-HT7 receptor function on mucosal
DCs will be important in determining the role of the 5-HT7
receptor in intestinal inflammation and to translate in vivo
findings.
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